TY - JOUR
T1 - The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease
AU - Gea, Joaquim
AU - Pascual, Sergi
AU - Castro-Acosta, Ady
AU - Hernández-Carcereny, Carmen
AU - Castelo, Robert
AU - Márquez-Martín, Eduardo
AU - Montón, Concepción
AU - Palou, Alexandre
AU - Faner, Rosa
AU - Furlong, Laura I.
AU - Seijo, Luis
AU - Sanz, Ferran
AU - Torà, Montserrat
AU - Vilaplana, Carles
AU - Casadevall, Carme
AU - López-Campos, José Luis
AU - Monsó, Eduard
AU - Peces-Barba, Germán
AU - Cosío, Borja G.
AU - Agustí, Alvar
AU - Admetlló, Mireia
AU - Alvarez-Martínez, Carlos
AU - Barreiro, Esther
AU - Casals, Ferran
AU - Córdova, Rocío
AU - García, Marian
AU - González-García, José G.
AU - Márquez, Eduardo
AU - Ormaza, Miren Josune
AU - Puigdevall, Pau
AU - Seijo, Luis
AU - Torralba, Yolanda
PY - 2019/2/1
Y1 - 2019/2/1
N2 - © 2018 SEPAR Chronic obstructive pulmonary disease (COPD) is an entity with a heterogeneous presentation. For this reason, attempts have been made to characterize different phenotypes and endotypes to enable a more individualized approach. The aim of the Biomarkers in COPD (BIOMEPOC) project is to identify useful biomarkers in blood to improve the characterization of patients. Clinical data and blood samples from a group of patients and healthy controls will be analyzed. The project will consist of an exploration phase and a validation phase. Analytical parameters in blood will be determined using standard techniques and certain ‘omics’ (transcriptomics, proteomics, and metabolomics). The former will be hypothesis-driven, whereas the latter will be exploratory. Finally, a multilevel analysis will be conducted. Currently, 269 patients and 83 controls have been recruited, and sample processing is beginning. Our hope is to use the results to identify new biomarkers that, alone or combined, will allow a better characterization of patients.
AB - © 2018 SEPAR Chronic obstructive pulmonary disease (COPD) is an entity with a heterogeneous presentation. For this reason, attempts have been made to characterize different phenotypes and endotypes to enable a more individualized approach. The aim of the Biomarkers in COPD (BIOMEPOC) project is to identify useful biomarkers in blood to improve the characterization of patients. Clinical data and blood samples from a group of patients and healthy controls will be analyzed. The project will consist of an exploration phase and a validation phase. Analytical parameters in blood will be determined using standard techniques and certain ‘omics’ (transcriptomics, proteomics, and metabolomics). The former will be hypothesis-driven, whereas the latter will be exploratory. Finally, a multilevel analysis will be conducted. Currently, 269 patients and 83 controls have been recruited, and sample processing is beginning. Our hope is to use the results to identify new biomarkers that, alone or combined, will allow a better characterization of patients.
KW - Biological markers
KW - COPD
KW - Endotypes
KW - Multilevel analysis
KW - Personalized medicine
U2 - 10.1016/j.arbres.2018.07.026
DO - 10.1016/j.arbres.2018.07.026
M3 - Article
C2 - 30343952
VL - 55
SP - 93
EP - 99
ER -